SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Recent community discussions surrounding Compound ($COMP) are focused on concerns about the Compound Foundation's financial sustainability, potential governance issues, and comparisons to other projects in the Real World Asset (RWA) space. Some investors are expressing worry about a possible deficit and its impact on the protocol's future, while others remain optimistic about Compound's role in the evolving crypto landscape. Bullish investors point to the formation of the Compound Foundation and institutional interest as reasons for optimism.

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token HMMM is trending as the community highlights its potential and notes its integration with Phantom Wallet. Social media buzz suggests growing interest and positive sentiment around HMMM, with many anticipating a potential breakout. Community members are using terms like "moon," "rocket," and "early entries" to describe their expectations for the token's performance.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and potential for significant upward movement, with some eyeing a potential Binance listing as a major catalyst. Community members are actively speculating on entry points and anticipating a breakout, citing its limited supply and previous highs as reasons for optimism. Recent integration with Aleph Zero is also being highlighted.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE is trending as community members discuss its recent price movements and potential for further gains, particularly in relation to BTC's performance. Some investors are highlighting the token's fundamentals, potential catalysts, and possible links to Coinbase, while others are closely watching for breakout opportunities and key resistance levels. The community is also weighing in on its trading platform and potential Binance listing.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as traders discuss its potential in the play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Community members are weighing in on entry points and whether it's still early to invest, while also noting its recent listing on Robinhood and its ecosystem of AI agents. The conversation highlights the potential for significant growth, although some caution against pump-and-dump schemes.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Energy prices are in focus as XOM trends, with community members discussing potential breakouts and resistance levels. Bullish sentiment is fueled by news of production milestones in Guyana and a new deepwater deal, while some analysts are focused on XOM's cash flow and valuation. Discussions also include potential impacts from geopolitical events and the possibility of XOM returning to Russia.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential, partnerships, and technology, particularly around privacy solutions and real-world asset tokenization. Recent news and developments, including its involvement with the Digital Euro project, have sparked conversations, though some express frustration with the token's price action relative to the news. Community members are also weighing in on potential price movements and long-term prospects.

AvePoint, Inc. operates as a digital collaboration innovator, which provides data management services. It develops, markets, and sells its suite of software solutions and services in North America, Europe, Australia, and Asia. The company was founded on July 24, 2001 and is headquartered in Jersey City, NJ.

AvePoint Inc - Ordinary Shares - Class A

AvePoint is trending due to Morgan Stanley initiating coverage as "overweight," calling it an "underappreciated" data security play, though some investors remain skeptical after years of stagnant growth since its SPAC days. Community discussions revolve around the company's potential, insider selling activity, and a recent settlement with investors over claims of a misleading de-SPAC merger in 2021. Some investors are optimistic about upcoming catalysts like the November quarterly report, while others express frustration with the stock's historical performance.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXPI is trending amidst discussions around potential earnings beats and strong automotive demand offsetting weakness in other sectors. The community is actively debating whether the stock is building a solid foundation for an explosive move, while also considering the impact of competitor activities and unusual options activity. Updates from SEMICON West 2025, focusing on AI demand and supply chain resilience, are adding to the conversation.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai ($FET) is trending as the community discusses its potential following the ASI merger, with some expressing frustration over price action while others remain optimistic about its long-term prospects in the AI sector; some users are noting the volume of FET being sold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</li><li>In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.</li><li>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.<br>&nbsp;</li></ul><p>Shares of Inhibrx Biosciences (INBX) jumped over 62% in the pre-market session on Friday after the company announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</p><p>The company investigated Ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma, a rare type of bone cancer that develops in the cartilage cells, most often affecting the pelvis, thigh, or upper arm.</p><h2 class="st-heading-2">What Was Observed In The Study?</h2><p>In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://inhibrxbiosciences.investorroom.com/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts">study</a>, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared with placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months with placebo. Progression-free survival (PFS) is the time a patient lives with a disease without worsening, from the start of treatment until disease progression or death.</p><p>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.</p><h2 class="st-heading-2">Safety Concerns</h2><p>Ozekibart was generally well tolerated, with a manageable safety profile, the company said. However, one liver damage-related fatal event occurred early in the study, it noted. The company mitigated the risk during the course of the trial by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, thereby reducing the overall incidence of liver-related treatment-related adverse events, it added.</p><p>Inhibrx is also studying the drug in colorectal cancer and ewing sarcoma in combination with other drugs. While colorectal cancer is a cancer that forms in the colon or rectum, ewing sarcoma is a type of cancer that forms in the bone or soft tissue.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/INBX"> INBX stock </a>jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Retail chatter around the stock jumped about 985% over the past 24 hours, according to Stocktwits data.</p><figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure><p>A Stocktwits user expects the stock to rally as high as over $70, citing the company’s first-mover advantage in developing drugs for chondrosarcoma.</p><p><stembedurl>https://stocktwits.com/spaumaki/message/633545900</stembedurl></p><p>INBX stock is up 84% this year.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reliance-increases-crude-imports-from-middle-east-u-s-amid-russian-crude-sanctions-report/cLGJZgVR3so">Reliance Increases Crude Imports From Middle East, U.S. Amid Russian Crude Sanctions: Report</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background.

Why Is INBX Stock Rising Today?

Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.

Equity

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion...

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma...

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance Inhibrx Biosciences Announces Loan Agreement with Oxford Finance PR Newswire SAN DIEGO, Jan. 13, 2025 SAN DIEGO, Jan. 13, 2025...

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results Inhibrx Biosciences Reports Third Quarter 2024 Financial Results PR Newswire SAN DIEGO, Nov. 14, 2024 SAN DIEGO, Nov. 14, 2024...

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation PR Newswire...

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PR...

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi PR Newswire SAN DIEGO, May 24, 2024 SAN DIEGO, May 24, 2024 /PRNewswire...

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off PR Newswire SAN DIEGO, May 10, 2024...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO PR Newswire NEW YORK, May 10, 2024 NEW YORK, May 10...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

INBX
Inhibrx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INBX News

INBXInhibrx Inc